The only sensing-enabled DBS system, now with the world’s first closed-loop feature for Parkinson's disease
The Percept™ family with BrainSense™ technology† is the only sensing-enabled DBS system offering insights into a patient’s condition inside and outside of the clinic throughout the patient journey.
BrainSense™ technology captures brain signals (local field potentials or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic. Clinicians can also correlate these brain signals with stimulation and patient-captured events such as medication, symptoms, or side effects.
See how BrainSense™ technology captures brain signals at the exact time a person with Parkinson’s disease experiences symptoms even when symptoms occur outside of an office visit. (This is an animated example representing a person with Parkinson’s disease.)
The BrainSense™ suite of tools offers decision-making support to select and optimize programming configurations and to maximize therapeutic results over time.
There are risks and benefits of DBS: Risks include surgical complications, infection, failure to deliver therapy as needed and/or worsening of some symptoms.
The Percept™ PC is a recharge free neurostimulator with sensing, directionality, and advanced programming capabilities for deep brain stimulation (DBS).
Percept™ RC is a rechargeable neurostimulator with sensing, directionality, and advanced programming capabilities for deep brain stimulation (DBS).
The SenSight™ directional DBS lead system combines the benefits of directionality with the power of sensing.
Medtronic MR Conditional◊ systems are backed by more than 14 years of MRI research and testing history.
Access on-demand DBS resources, procedural videos, webinars, and more at Medtronic Academy.
See reimbursement codes and information for Medtronic DBS.
Medtronic’s DBS therapy is approved for five indications: Parkinson’s disease, essential tremor, dystonia, obsessive-compulsive disorder (OCD), and epilepsy. Indications vary by product, refer to product labeling for details.
Humanitarian device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.
† The sensing feature of the Percept™ PC system and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. The majority of patients with Parkinson’s disease have an identifiable signal. Signal may not be present or measurable in patients treated for essential tremor, dystonia, epilepsy or obsessive-compulsive disorder. Humanitarian device: The effectiveness of these devices for the treatment of dystonia or obsessive-compulsive disorder has not been demonstrated.
‡ Compared to traditional monopolar review for Parkinson’s disease. Based on a randomized control trial, Thompson et al. 2024.
§ Results presented for dual threshold aDBS. N=40. Based on results from a single-blinded, randomized, crossover trial.
◊ Medtronic DBS systems are MR Conditional. Refer to product labeling for full list of conditions.
